Back to discover
Disease

Vitamin D Deficiency

Late-stage therapeutic developmentEmerging researchCooling momentum
15
Publications
21
Clinical trials
7
Related conditions
2
Related treatments
1
Related proteins
2025
Latest publication
Current focus
Therapeutic developmentInflammation & immunityMetabolic & lifestyle factors

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Imigluceraseapproved

Approval — Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in pa… (1997)

Research-associated treatments

Clinical trials

17 sponsors · 3 new · 1 completed in the last 12 months (net +3)

The current development programme across all trial phases.

Clinical programme
21
All trials
6
Active
14
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
1997emaApprovalImiglucerase· Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

15 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20062025
Recent publications
Major themes8
  • Vitamin D Deficiency6
  • Vitamin D4
  • Autoimmune Diseases1
  • Betacoronavirus1
  • Cardiovascular Diseases1
  • COVID-191
  • COVID-19 Drug Treatment1
  • Diabetes Mellitus, Type 11
Leading journals6
  • Nutrients5
  • International journal of molecular sciences4
  • Andrology1
  • Biomolecules1
  • Cells1
  • Epidemiology and infection1
Leading researchers8
  • Argano C2
  • Corrao S2
  • Grant WB2
  • Holick MF2
  • Orlando V2
  • Torres A2
  • Wimalawansa SJ2
  • Aggeletopoulou I1
Affiliations (unnormalised)6
  • University of Palermo2
  • and Health Research Center1
  • Atascadero State Hospital1
  • Cardiometabolic & Endocrine Institute1
  • CardioMetabolic & Endocrine Institute1
  • Center for Advancing Exercise and Nutrition Research on Aging1

Disease biology

1 match

Key proteins & gene products studied in this disease. Number shows shared papers.

Related conditions

7 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Vitamin D deficiency is a nutritional disorder caused by inadequate vitamin D intake, insufficient skin production, poor absorption from the diet, or abnormal conversion to active metabolites. It is clinically manifested as rickets in children and osteomalacia in adults.

Causes

The grounding supports several causes: low dietary vitamin D, insufficient production in the skin from inadequate sun exposure, inadequate absorption from the diet, and abnormal conversion of vitamin D to its bioactive metabolites. The literature also notes that calcium deficiency can contribute to the clinical picture of rickets alongside vitamin D deficiency.

Pathophysiology

Vitamin D is biologically inert and is converted in the liver to 25-hydroxyvitamin D and then in the kidneys to 1,25-dihydroxyvitamin D, the active form that regulates calcium, phosphorus, and bone metabolism. Deficiency reduces this hormonal activity and disrupts bone mineralization, leading to rickets in children and osteomalacia in adults. The grounding also links active vitamin D to immune modulation, including effects on inflammatory cytokines and antimicrobial peptides, but this is presented as broader biology rather than the core deficiency mechanism.

Risk factors

Insufficient sun exposure is a supported risk factor, and vitamin D deficiency is described as common in winter. The literature also indicates that inadequate dietary intake and impaired absorption increase risk, and that calcium deficiency may worsen related skeletal disease. Beyond skeletal outcomes, the reviews associate vitamin D deficiency with increased incidence or aggravation of infectious and inflammatory diseases, but these are associations rather than established causal risk factors for deficiency itself.

Current standard of care

The grounding supports vitamin D supplementation as the main treatment and prevention approach, using vitamin D as a drug class and cholecalciferol as a co-studied form. Calcium is also co-studied, consistent with combined nutritional management in deficiency-related bone disease. The literature additionally mentions prevention and control measures such as sensible sun exposure and food fortification, but does not provide specific regimens.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.